TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34959963
Drug: Goji berries
Normalized name: GOJI BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goji berries (28 g, five times weekly for 90 days)
Study: 34959963
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (supplement containing 6 mg L and 4 mg Z, five times weekly for 90 days)
Study: 33983449
Drug: Intradialytic cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic cycling (IDC) - 6-month programme, thrice weekly, moderate intensity cycling (RPE 12-14)
Study: 35224215
Drug: Vaginal washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal washing with 20 cc of normal saline 0.9% before Misoprostol insertion
Study: 33176826
Drug: Encapsulated natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated natural mushroom-derived vitamin D2 (25 μg or 1000 IU)
Study: 33176826
Drug: Matched-dose encapsulated
Normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-dose encapsulated vitamin D3 (25 μg or 1000 IU)
Study: 35288397
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg empagliflozin for 14 days
Study: 35597230
Drug: Higher anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher anthocyanin intake (>10 mg/d)
Study: 35597230
Drug: Lower anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower anthocyanin intake (<10 mg/d)
Study: 32895971
Drug: Enteral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral erythromycin estolate (250 mg) + Intravenous metoclopramide (10 mg every 6-8 hours)
Study: 32895971
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (10 mg every 6-8 hours) + Placebo (every 6 hours for 7 days)
Study: 32032916
Drug: Ondansetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.2 mg.kg‐1
Study: 32032916
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg.kg‐1
Study: 36241872
Drug: ivabradine (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5-7.5 mg)
Study: 39705390
Drug: Clopidogrel-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin
Study: 35373583
Drug: Dual Antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Antiplatelet Therapy (aspirin plus clopidogrel)
Study: 34768338
Drug: Fixed-dose oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose oxygen treatment
Study: 32951712
Drug: Vacuum myofascial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum myofascial therapy device (VT)
Study: 32951712
Drug: Comparison physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison physical therapy program (PTP)
Study: 34872625
Drug: Integrated cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive-behavioral therapy (CBT) for ED-PTSD
Study: 32769842
Drug: Lotrafilcon B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafilcon B lenses packaged in and cared for with EOBO-containing solutions (CLEAR CARE PLUS with HydraGlyde or OPTI-FREE PUREMOIST)
Study: 36397223
Drug: Five-element music
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-element music therapy, 30 min each session, once every two days, 3 treatments a week for 4 weeks.
Study: 36397223
Drug: Five-element music
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-element music therapy.
Study: 36129521
Drug: Azithromycin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (n = 13, standard dose every 10 days)
Study: 36129521
Drug: NB‐UVB (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB (n = 11, thrice weekly)
Study: 32383615
Drug: Aminophylline (5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5mg/kg slow intravenous injection)
Study: 32383615
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL/kg of intravenous 10% solution of dextrose saline)
Study: 34534071
Drug: 5-week adjunctive
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-week adjunctive bright light therapy with a gradual advance protocol
Study: 35726738
Drug: Colorado Protocol
Normalized name: influenza B virus B/Colorado/06/2017 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorado Protocol (aspirin, steroid, and antibiotic)
Study: 35791755
Drug: Mirikizumab 250
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 250 mg Q4W
Study: 35791755
Drug: Mirikizumab 250
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 250 mg Q4W/125 mg Q8W
Study: 35791755
Drug: Mirikizumab 250
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 250 mg Q4W/250 mg Q8W
Study: 33080034
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (10,000 lux)
Study: 34839447
Drug: Fungal keratitis
Normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungal keratitis treatment
Study: 35080187
Drug: Bevacizumab 2.5
Normalized name: Bevacizumab 2.5 MG/0.1 ML Intraocular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 2.5 mg/kg d1, d8 (group A)
Study: 35080187
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg d1, d8 (group B)
Study: 35080187
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg d1, d8 (group C)
Study: 33255704
Drug: Psychological Capital
Normalized name: Lespedeza capitata flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological Capital Intervention (PCI) using a daily online self-learning approach
Study: 616886769
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine-based nursing care
Study: 32696031
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus metronidazole (AM+MT) combined with SD
Study: 32581088
Drug: Rituximab (4×375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (4×375 mg/m2) and glucocorticoids (higher or lower dose regimen)
Study: 36183042
Drug: Subtenon 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon 20-mg triamcinolone injection (TA group)
Study: 34699409
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg once daily for 28 days
Study: 32988518
Drug: Feeding frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feeding frequency 3 times daily
Study: 32988518
Drug: Feeding frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feeding frequency 4 times daily
Study: 32988518
Drug: Different feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different feeding frequencies (3 to 5 times daily)
Study: 33449304
Drug: Capsaicinoids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicinoids at 10 μmol/L
Study: 33449304
Drug: Capsaicinoids preconditioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicinoids preconditioning at 10 μmol/L over 5 min
Study: 33449304
Drug: Capsaicinoids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicinoids at 50 μmol/L
Study: 32845283
Drug: Telmisartan, 40
Normalized name: Telmisartan, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan, 40 mg
Study: 34197764
Drug: CoronaVac 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 1.5 μg
Study: 34197764
Drug: CoronaVac 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 3.0 μg
Study: 34197764
Drug: CoronaVac 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 1.5 μg (phase 2)
Study: 34197764
Drug: CoronaVac 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 3.0 μg (phase 2)
Study: 32920241
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of outcome- and process-based incentives
Study: 36078584
Drug: HRV-guided training
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRV-guided training (HRV-G)
Study: 36078179
Drug: Predefined training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predefined training (PRED-G)
Study: 36078179
Drug: Both HRV-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HRV-G and PRED-G
Study: 32150232
Drug: Gabapentin up
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin up to 1200 mg/d, orally, with 9 medical management visits (20 minutes each)
Study: 32540236
Drug: Topical treatments
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatments for actinic keratosis
Study: 32540236
Drug: DCE (Discrete
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCE (Discrete Choice Experiment) at baseline and final post-treatment assessment
Study: 36212173
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg·kg‐1·h‐1 before and during anesthesia, 0.2 μg·kg‐1·h‐1 after induction)
Study: 33114585
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g protein (MOD)
Study: 33114585
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g protein (HIGH)
Study: 33867179
Drug: Sucralfate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (20 mg/kg per dose up to 1 g)
Study: 32867790
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing cyproterone acetate (CPA)
Study: 32867790
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing desogestrel (DSG)
Study: 32867790
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing drospirenone (DRSP)
Study: 32867790
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing levonorgestrel (LNG)
Study: 33787345
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone at a dose of 1 mg/kg/day followed by weekly stepwise tapering in steps of 10 mg/day
Study: 32952824
Drug: Ivermectin administration
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin administration over seven years
Study: 36324229
Drug: Interferon β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β‐1a (7.5–30 μg)
Study: 36324229
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon β‐1a (31.25–125 μg)
Study: 35259753
Drug: Control (Medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Medication, massage, and facial exercise)
Study: 35716984
Drug: Betadine® Surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betadine® Surgical Scrub and Betadine® 5% solution (povidone‐iodine)
Study: 38439092
Drug: Group Schema
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Schema Therapy (GST)
Study: 36209067
Drug: Individual Schema
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Schema Therapy (IST)
Study: 33933271
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (gas flow 70 L min−1, inspired oxygen fraction 0.50)
Study: 33933271
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen (delivered via nasal cannula or face mask at 6 L min−1 or nasopharyngeal tube at 5 L min−1)
Study: 34600960
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with fluoxetine
Study: 33893337
Drug: Lower PaO2/FiO2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower PaO2/FiO2, 2 days after treatment
Study: 36170988
Drug: Control (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (monthly text message)
Study: 36210358
Drug: Video augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video augmented mirror therapy (MTVADG)
Study: 36210358
Drug: Traditional mirror
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional mirror therapy (TMTG)
Study: 34371893
Drug: High flavonoid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavonoid foods added to daily diet
Study: 35239783
Drug: Caffeine (CAF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF, 5 mg/kg)
Study: 32801255
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (Hb <7 g/dl)
Study: 32801255
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hb <8 g/dl)
Study: 33185650
Drug: Vericiguat titrated
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vericiguat titrated to 10 mg daily
Study: 36283068
Drug: Silane application
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silane application with universal adhesives (Scotchbond Universal, All‐Bond Universal, G‐Premio Bond, Clearfil SE Bond)
Study: 33136237
Drug: AAV-based gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV-based gene therapy (e.g., Luxturna® - voretigene neparvovec‐rzyl)
Study: 33136237
Drug: AAV-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV-based therapies
Study: 32586939
Drug: Failure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure to clear CTCs during treatment
Study: 36240214
Drug: Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Management Review (MMR) service
Study: 32379581
Drug: Ultrasound-guided PRP
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided PRP injection into pathological shoulder tendons targeting the supraspinatus
Study: 32427108
Drug: iCAN-DO intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCAN-DO intervention (Step 1: access to psychoeducational material and peer support; Step 2: internet-based cognitive behavioral therapy)
Study: 32714133
Drug: Regular therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapies
Study: 34791350
Drug: 2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 6 and 14 weeks
Study: 34791350
Drug: 2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 10 and 14 weeks
Study: 34791350
Drug: 1 full
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 full dose of IPV (0.5mL, intramuscular) at age 14 weeks
Study: 32744906
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids with acupuncture
Study: 32564093
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral micronized progesterone at bedtime
Study: 35033346
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation, 60 g of product containing 30 g of FO daily
Study: 35033346
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil (CO) supplementation, 30 mL daily
Study: 34925649
Drug: Ramipril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25 mg/d)
Study: 34925649
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg/d)
Study: 33323306
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (2 mA current, 20 minutes per session, repeated once daily for 5 consecutive days)
Study: 33323306
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received acetaminophen
Study: 32074356
Drug: 2% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% pilocarpine ophthalmic solution (two drops)
Study: 32074356
Drug: 2% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% pilocarpine ophthalmic solution (three drops)
Study: 32404782
Drug: MF59-adjuvanted quadrivalent
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted quadrivalent influenza vaccine (aIIV4)
Study: 32404782
Drug: Nonadjuvanted comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted comparator influenza vaccine
Study: 33820576
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) 1 capsule containing 1×10^10 cells twice daily (n = 44)
Study: 33481771
Drug: 5-hydroxyindole (5-HI)
Normalized name: Butylated Hydroxyanisole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxyindole (5-HI) administered orally in rats
Study: 33092819
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with cisplatin/paclitaxel q21 followed by cold‐knife conization (CKC)
Study: 34081314
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention (reverse Trendelenburg position, dysphagia screening, oral care, vaccinations)
Study: 32898006
Drug: Systemic anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic anticoagulation (SAC) therapy
Study: 33506031
Drug: Focused Shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused Shockwave Therapy (F‐SWT)
Study: 33506031
Drug: Radial Shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Shockwave Therapy (R‐SWT)
Study: 37071834
Drug: Cisplatin combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin combination chemotherapy
Study: 32402558
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose alone (S24%)
Study: 32526534
Drug: Collaborative Care/Stepped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care/Stepped Care (CC/SC)
Study: 34307681
Drug: Progressive Resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Resistance Exercises plus Manual Therapy (PRE plus MT)
Study: 35197068
Drug: Web-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based health education regarding HPV and HPV vaccines for seven days
Study: 33226075
Drug: Housing subsidy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing subsidy (MTO voucher treatment)
Study: 33123802
Drug: DNX HBr
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNX HBr hemihydrate tablet formulations in fed state (high fat)
Study: 33123802
Drug: DNX HBr
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNX HBr monohydrate formulation
Study: 33609343
Drug: Progressive Physical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Physical Therapy (PPT)
Study: 33609343
Drug: Maintenance Physical
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Physical Therapy (MPT)
Study: 32910735
Drug: Experimental sEMG
Normalized name: Semglee
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experimental sEMG patch
Study: 33845988
Drug: Hyaluronic acid-enriched
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid-enriched transfer medium (EmbryoGlue, 0.5 mg/mL)
Study: 33845988
Drug: Standard transfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard transfer medium (supplemented G-2, 0.125 mg/mL)
Study: 33789642
Drug: Immediate telemedicine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate telemedicine linkage to the provider and transportation to pick up induction prescription or attend intake appointment.
Study: 33789642
Drug: Standard referral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard referral to treatment.
Study: 33478976
Drug: Short regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short regimen (40 mg/m2 on alternate days for 2 weeks)
Study: 33478976
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (40 mg/m2 on alternate days for 4 weeks)
Study: 36343085
Drug: Healbot T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healbot T with constraint-induced movement therapy (CIMT) mode (CIMT group; n = 10)
Study: 35119520
Drug: Fitbit Flex™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitbit Flex™ and daily text messages for 12 weeks